Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study of the New Adjuvant Treatment of HER-2 Positive Resectable Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab

NCT05583383 is registered in ClinicalTrials.gov with Henan Cancer Hospital as lead sponsor.

NCT NCT05583383
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05583383 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study of the New Adjuvant Treatment of HER-2 Positive Resectable Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab
Lead sponsor
Henan Cancer Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
March 31, 2022
Completion date
March 31, 2025
Enrollment
62 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric adenocarcinoma